## Jason Gertz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1229770/publications.pdf Version: 2024-02-01



LASON CEPTZ

#	Article	IF	CITATIONS
1	Hotspot <i>ESR1</i> Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer Research, 2022, 82, 1321-1339.	0.9	30
2	A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nature Cancer, 2022, 3, 232-250.	13.2	133
3	ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nature Communications, 2022, 13, 2011.	12.8	29
4	Comprehensive evaluation and efficient classification of BRCA1 RING domain missense substitutions. American Journal of Human Genetics, 2022, 109, 1153-1174.	6.2	6
5	Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects. Cancer Research, 2021, 81, 539-551.	0.9	35
6	Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of <i>ESR1</i> -Mutant Breast Cancer. Cancer Research, 2021, 81, 732-746.	0.9	34
7	A Positive Feedback Loop Between TGFβ and Androgen Receptor Supports Triple-negative Breast Cancer Anoikis Resistance. Endocrinology, 2021, 162, .	2.8	13
8	Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4. Gut, 2021, 70, 900-914.	12.1	19
9	Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	28
10	Genetic demultiplexing of pooled single-cell RNA-sequencing samples in cancer facilitates effective experimental design. GigaScience, 2021, 10, .	6.4	17
11	A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer. Nature Communications, 2021, 12, 7139.	12.8	12
12	Regulatory sharing between estrogen receptor α bound enhancers. Nucleic Acids Research, 2020, 48, 6597-6610.	14.5	7
13	MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. Cancer Cell, 2020, 38, 60-78.e12.	16.8	262
14	Synergistic CRISPRa-Regulated Chondrogenic Extracellular Matrix Deposition Without Exogenous Growth Factors. Tissue Engineering - Part A, 2020, 26, 1169-1179.	3.1	11
15	ETV4 Is Necessary for Estrogen Signaling and Growth in Endometrial Cancer Cells. Cancer Research, 2020, 80, 1234-1245.	0.9	39
16	XPRESSyourself: Enhancing, standardizing, and automating ribosome profiling computational analyses yields improved insight into data. PLoS Computational Biology, 2020, 16, e1007625.	3.2	15
17	Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer. Genome Research, 2019, 29, 1429-1441.	5.5	27
18	FFPEcap-seq: a method for sequencing capped RNAs in formalin-fixed paraffin-embedded samples. Genome Research, 2019, 29, 1826-1835.	5.5	9

JASON GERTZ

#	Article	IF	CITATIONS
19	Lentiviral CRISPR Epigenome Editing of Inflammatory Receptors as a Gene Therapy Strategy for Disc Degeneration. Human Gene Therapy, 2019, 30, 1161-1175.	2.7	44
20	MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion. Clinical Cancer Research, 2019, 25, 5107-5121.	7.0	117
21	Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions. Hormones and Cancer, 2019, 10, 51-63.	4.9	164
22	Sufficiency analysis of estrogen responsive enhancers using synthetic activators. Life Science Alliance, 2019, 2, e201900497.	2.8	10
23	CIGGLE: a search engine for large-scale integrated genome analysis. Nature Methods, 2018, 15, 123-126.	19.0	154
24	Clinical and Genomic Crosstalk between Glucocorticoid Receptor and Estrogen Receptor $\hat{I}\pm$ In Endometrial Cancer. Cell Reports, 2018, 22, 2995-3005.	6.4	52
25	Dissection of Enhancer Function Using Multiplex CRISPR-based Enhancer Interference in Cell Lines. Journal of Visualized Experiments, 2018, , .	0.3	7
26	MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell, 2017, 31, 270-285.	16.8	406
27	Multiplex Enhancer Interference Reveals Collaborative Control of Gene Regulation by Estrogen Receptor α-Bound Enhancers. Cell Systems, 2017, 5, 333-344.e5.	6.2	85
28	CRISPR Epigenome Editing of AKAP150 in DRG Neurons Abolishes Degenerative IVD-Induced Neuronal Activation. Molecular Therapy, 2017, 25, 2014-2027.	8.2	35
29	Post-mortem molecular profiling of three psychiatric disorders. Genome Medicine, 2017, 9, 72.	8.2	147
30	Genomic regulation of invasion by STAT3 in triple negative breast cancer. Oncotarget, 2017, 8, 8226-8238.	1.8	69
31	GENT-18. DIFFERENTIAL BRD4-BOUND STRETCH/SUPER ENHANCERS DRIVE CRITICAL SEX DIFFERENCES IN GBM PHENOTYPE. Neuro-Oncology, 2016, 18, vi77-vi77.	1.2	0
32	Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus. Cancer Research, 2016, 76, 1916-1925.	0.9	7
33	Cooperative Dynamics of AR and ER Activity in Breast Cancer. Molecular Cancer Research, 2016, 14, 1054-1067.	3.4	114
34	Distinct gene regulatory programs define the inhibitory effects of liver X receptors and PPARG on cancer cell proliferation. Genome Medicine, 2016, 8, 74.	8.2	43
35	RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with longâ€ŧerm survival and reveals a role for <i>ANGPTL4</i> . Molecular Oncology, 2016, 10, 1169-1182.	4.6	70
36	Improved survival among colon cancer patients with increased differentially expressed pathways. BMC Medicine, 2015, 13, 75.	5.5	18

JASON GERTZ

#	Article	IF	CITATIONS
37	Promoter-distal RNA polymerase II binding discriminates active from inactive CCAAT/ enhancer-binding protein beta binding sites. Genome Research, 2015, 25, 1791-1800.	5.5	30
38	From single-cell to cell-pool transcriptomes: Stochasticity in gene expression and RNA splicing. Genome Research, 2014, 24, 496-510.	5.5	470
39	Recurrent read-through fusion transcripts in breast cancer. Breast Cancer Research and Treatment, 2014, 146, 287-297.	2.5	141
40	Distinct Properties of Cell-Type-Specific and Shared Transcription Factor Binding Sites. Molecular Cell, 2013, 52, 25-36.	9.7	283
41	Mapping genome-wide transcription factor binding sites in frozen tissues. Epigenetics and Chromatin, 2013, 6, 30.	3.9	29
42	Dynamic DNA methylation across diverse human cell lines and tissues. Genome Research, 2013, 23, 555-567.	5.5	614
43	Early de novo DNA methylation and prolonged demethylation in the muscle lineage. Epigenetics, 2013, 8, 317-332.	2.7	85
44	Research Resource: Enhanced Genome-Wide Occupancy of Estrogen Receptor α by the Cochaperone p23 in Breast Cancer Cells. Molecular Endocrinology, 2012, 26, 194-202.	3.7	19
45	Widespread plasticity in CTCF occupancy linked to DNA methylation. Genome Research, 2012, 22, 1680-1688.	5.5	494
46	Transposase mediated construction of RNA-seq libraries. Genome Research, 2012, 22, 134-141.	5.5	85
47	ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Research, 2012, 22, 1813-1831.	5.5	1,708
48	The Hypersensitive Glucocorticoid Response Specifically Regulates Period 1 and Expression of Circadian Genes. Molecular and Cellular Biology, 2012, 32, 3756-3767.	2.3	122
49	Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Research, 2012, 22, 2153-2162.	5.5	121
50	CTCF/cohesin-mediated DNA looping is required for protocadherin α promoter choice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 21081-21086.	7.1	218
51	Architecture of the human regulatory network derived from ENCODE data. Nature, 2012, 489, 91-100.	27.8	1,384
52	Effects of sequence variation on differential allelic transcription factor occupancy and gene expression. Genome Research, 2012, 22, 860-869.	5.5	150
53	Allele-specific distribution of RNA polymerase II on female X chromosomes. Human Molecular Genetics, 2011, 20, 3964-3973.	2.9	34
54	ll̂ºB kinase Îμ (IKKÎμ) regulates the balance between type I and type II interferon responses. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21170-21175.	7.1	105

Jason Gertz

#	Article	IF	CITATIONS
55	Analysis of DNA Methylation in a Three-Generation Family Reveals Widespread Genetic Influence on Epigenetic Regulation. PLoS Genetics, 2011, 7, e1002228.	3.5	256
56	Epistasis in a quantitative trait captured by a molecular model of transcription factor interactions. Theoretical Population Biology, 2010, 77, 1-5.	1.1	29
57	Environmentâ€specific combinatorial <i>cis</i> â€regulation in synthetic promoters. Molecular Systems Biology, 2009, 5, 244.	7.2	45
58	Analysis of combinatorial cis-regulation in synthetic and genomic promoters. Nature, 2009, 457, 215-218.	27.8	287
59	A cis-regulatory logic simulator. BMC Bioinformatics, 2007, 8, 272.	2.6	1
60	Phylogeny based discovery of regulatory elements. BMC Bioinformatics, 2006, 7, 266.	2.6	9
61	Discovery, validation, and genetic dissection of transcription factor binding sites by comparative and functional genomics. Genome Research. 2005. 15. 1145-1152.	5.5	31